Baird analyst Colleen Kusy downgraded Surface Oncology (SURF) to Neutral from Outperform after it was announced that Coherus Biosciences (CHRS) will acquire Surface Oncology in a stock transaction valued at about $65M, or about $45M enterprise value. In light of the early-stage for both of Surface’s two lead assets, SRF388 and SRF114, and the current capital markets, the firm expects this deal to go through.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SURF:
- Surface Oncology downgraded to Neutral from Buy at H.C. Wainwright
- Surface Oncology implements 50% workforce reduction
- Coherus to Acquire Surface Oncology
- Coherus Biosciences, Surface Oncology enter definitive merger agreement
- Surface Oncology (SURF) Q1 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue